VIA
FDMT icon

Vident Investment Advisory’s 4D Molecular Therapeutics FDMT Stock Holding History

Vident Investment Advisory’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,521
Closed -$205K – 1183
2021
Q2 		$205K Buy
+8,521
New +$261K 0.01% 1050

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Vident Investment Advisory's FDMT Position: Q3 2021 in Review

Vident Investment Advisory sold out of 4D Molecular Therapeutics (FDMT) in Q3 2021, closing a stake of 8,521 shares — an estimated $205K sold.

Vident Investment Advisory first reported a position in FDMT in Q2 2021 and held it in 1 quarter. The position peaked at $205K in Q2 2021. 63 funds tracked by Wall St. Rank hold FDMT as of Q3 2021.

  • Vident Investment Advisory reported no remaining 4D Molecular Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Vident Investment Advisory sold 8,521 4D Molecular Therapeutics shares in Q3 2021, an estimated $205K.
  • Vident Investment Advisory first reported a position in 4D Molecular Therapeutics in Q2 2021 and held it in 1 quarter.
  • Vident Investment Advisory's 4D Molecular Therapeutics position peaked at $205K in Q2 2021.
  • 63 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2021.

Based on Vident Investment Advisory's 13F filing for Q3 2021, filed 12 Nov 2021.